Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Arizona State Retirement System

Arizona State Retirement System lifted its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 19.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,596 shares of the company’s stock after buying an additional 2,708 shares during the quarter. Arizona State Retirement System’s holdings in Viridian Therapeutics were worth $318,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. raised its position in Viridian Therapeutics by 1,603.4% during the third quarter. Principal Financial Group Inc. now owns 172,810 shares of the company’s stock worth $3,931,000 after acquiring an additional 162,665 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Viridian Therapeutics during the 3rd quarter worth approximately $208,000. Intech Investment Management LLC acquired a new position in shares of Viridian Therapeutics during the 3rd quarter worth approximately $422,000. Charles Schwab Investment Management Inc. lifted its stake in Viridian Therapeutics by 6.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 516,213 shares of the company’s stock valued at $11,744,000 after buying an additional 32,292 shares in the last quarter. Finally, Algert Global LLC grew its holdings in Viridian Therapeutics by 107.1% during the 3rd quarter. Algert Global LLC now owns 114,913 shares of the company’s stock valued at $2,614,000 after buying an additional 59,420 shares during the last quarter.

Viridian Therapeutics Stock Up 0.7 %

Shares of NASDAQ VRDN opened at $15.92 on Friday. The stock has a market capitalization of $1.30 billion, a PE ratio of -3.69 and a beta of 1.05. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a fifty day moving average of $17.43 and a 200-day moving average of $19.70. Viridian Therapeutics, Inc. has a 52-week low of $11.40 and a 52-week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. On average, analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on VRDN shares. Wells Fargo & Company reissued an “equal weight” rating and issued a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. TD Cowen began coverage on shares of Viridian Therapeutics in a report on Monday, November 25th. They issued a “buy” rating on the stock. Needham & Company LLC reiterated a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research report on Monday, December 16th. Finally, Royal Bank of Canada raised their target price on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 17th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $35.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.